State Street’s LB Pharmaceuticals LBRX Stock Holding History

State Street’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$27.1M	Buy	705,405 +103,377	+17%	+$4.27M	﹤0.01%	2165
2026 Q2	$19.5M	Buy	602,028 +97,655	+19%	+$2.87M	﹤0.01%	2399
2026 Q1	$12.4M	Buy	504,373 +254,343	+102%	+$5.87M	﹤0.01%	2491
2025 Q4	$5.57M	Buy	+250,030	New	+$4.37M	﹤0.01%	2947

Other funds holding LBRX

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

State Street's LBRX Position: Q3 2026 in Review

State Street increased its LB Pharmaceuticals (LBRX) stake by 17% in Q3 2026, buying an estimated $4.27M and bringing the position to 705,405 shares worth $27.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

State Street first reported a position in LBRX in Q4 2025 and has held it in 4 quarters since. 63 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

State Street held 705,405 shares of LB Pharmaceuticals worth $27.1M as of Q3 2026.
State Street bought 103,377 LB Pharmaceuticals shares in Q3 2026, an estimated $4.27M.
LB Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q3 2026, its #2165 holding.
State Street first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
63 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.